Dr. Somer on Immunotherapy Combinations in mRCC

Video

Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in metastatic renal cell carcinoma.

Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in patients with metastatic renal cell carcinoma (mRCC).

In the CheckMate-214 study, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a clear survival advantage over the frontline standard-of-care sunitinib (Sutent) in patients with previously untreated mRCC. With the proof of concept for immunotherapy in this setting, researchers are interested in exploring further combinations.

The field is likely heading in the direction of combining checkpoint inhibitors with VEGF tyrosine kinase inhibitors or additional immunotherapy options that provide synergy. Somer says the idea is that the mechanisms of action of these agents when used in combination will be more effective than their use as single agents. The short-term hope is that this will lead to deeper and durable responses, but the long-term goal is to cure more patients with mRCC, Somer concludes.

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD